ROSE YEN, L.AC., DIPL.O.M.
Acupuncture at Mission St, San Francisco, CA
License number
California 10138
Category
Acupuncture
Type
Acupuncturist
Address
Address
2588 Mission St SUITE 204, San Francisco, CA 94110
Phone
(415) 812-2101
Personal information
See more information about ROSE YEN at radaris.comName
Address
Phone
263 Rhine St, Daly City, CA 94014
1156 Shotwell St, San Francisco, CA 94110
1356 Torrance Ave, Sunnyvale, CA 94089
263 Rhine St, Daly City, CA 94014
Professional information
Senior Research Associate At Rigel
Position:
Senior Research Associate at Rigel, Senior Research Associate at Rigel Pharmaceuticals, Inc.
Location:
San Francisco Bay Area
Industry:
Pharmaceuticals
Work:
Rigel
since 2008
-
Senior Research Associate
Rigel Pharmaceuticals, Inc.
since 2008
-
Senior Research Associate
Theravance
Apr 2005 - Jun 2008
-
Research Associate
Essential Therapeutics
1996 - 2002
-
Research Associate
Microcide
1996 - 2002
-
Research Associate
Education:
McGill University
B.Sc., Chemistry
B.Sc., Chemistry
Rose Yen, San Francisco CA - LAC
Specialties:
Acupuncture
Address:
2588 Mission St SUITE 204, San Francisco 94110
Languages:
English
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
2012001, Jan 12, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/241037
Inventors:
Hui Li - Santa Clara CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
International Classification:
C07F 9/08
US Classification:
544243
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
2012001, Jan 19, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/241024
Inventors:
Hui Li - Santa Clara CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
International Classification:
C07D 413/12
US Classification:
544324
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
2012001, Jan 19, 2012
Filed:
Sep 22, 2011
Appl. No.:
13/241041
Inventors:
Hui Li - Santa Clara CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
International Classification:
C07D 413/12
US Classification:
5462717
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
2013009, Apr 11, 2013
Filed:
Nov 26, 2012
Appl. No.:
13/685433
Inventors:
RIGEL PHARMACEUTICALS, INC. - SOUTH SAN FRANCISCO CA, US
THILO J. HECKRODT - SAN FRANCISCO CA, US
YAN CHEN - FOSTER CITY CA, US
DARREN JOHN MCMURTRIE - FOSTER CITY CA, US
VANESSA TAYLOR - SAN FRANCISCO CA, US
RAJINDER SINGH - BELMONT CA, US
PINGYU DING - FOSTER CITY CA, US
ROSE YEN - SAN FRANCISCO CA, US
THILO J. HECKRODT - SAN FRANCISCO CA, US
YAN CHEN - FOSTER CITY CA, US
DARREN JOHN MCMURTRIE - FOSTER CITY CA, US
VANESSA TAYLOR - SAN FRANCISCO CA, US
RAJINDER SINGH - BELMONT CA, US
PINGYU DING - FOSTER CITY CA, US
ROSE YEN - SAN FRANCISCO CA, US
Assignee:
RIGEL PHARMACEUTICALS, INC. - SOUTH SAN FRANCISCO CA
International Classification:
C07D 413/12
US Classification:
514 80, 544323, 435184, 514275, 544232
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
Protein Kinase C Inhibitors And Uses Thereof
US Patent:
2013033, Dec 12, 2013
Filed:
Apr 4, 2013
Appl. No.:
13/857028
Inventors:
Rigel Pharmaceuticals, Inc. - , US
Matthew Duncton - San Bruno CA, US
Jing Zhang - Mercer Island WA, US
Salvador Alvarez - Fremont CA, US
Kin Tso - San Francisco CA, US
Sacha Holland - San Francisco CA, US
Rose Yen - San Francisco CA, US
Rao Kolluri - Foster City CA, US
Thilo Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Esteban Masuda - Menlo Park CA, US
Hui Li - Santa Clara CA, US
Donald G. Payan - Hillsborough CA, US
Matthew Duncton - San Bruno CA, US
Jing Zhang - Mercer Island WA, US
Salvador Alvarez - Fremont CA, US
Kin Tso - San Francisco CA, US
Sacha Holland - San Francisco CA, US
Rose Yen - San Francisco CA, US
Rao Kolluri - Foster City CA, US
Thilo Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Esteban Masuda - Menlo Park CA, US
Hui Li - Santa Clara CA, US
Donald G. Payan - Hillsborough CA, US
International Classification:
C07D 471/04, C07D 519/00
US Classification:
51421021, 544324, 514275, 435184, 544105, 5142305, 544101, 5142302, 544230, 544122, 5142332, 540548, 51421112, 544 71
Abstract:
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
8324200, Dec 4, 2012
Filed:
Jan 22, 2010
Appl. No.:
12/692493
Inventors:
Hui Li - Santa Clara CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Burlingame CA, US
Darren John McMurtrie - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Sambaiah Thota - Woburn MA, US
Rose Yen - San Francisco CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Burlingame CA, US
Darren John McMurtrie - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Sambaiah Thota - Woburn MA, US
Rose Yen - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/33, A61K 31/55, A61K 31/505, A61K 31/535, C07D 243/06, C07D 413/14, C07D 401/14
US Classification:
51421021, 514275, 514221, 5142338, 5142345, 540556, 544122, 544324
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Diamide Compounds Having Muscarinic Receptor Antagonist And Beta2 Adrenergic Receptor Agonist Activity
US Patent:
2013033, Dec 12, 2013
Filed:
Aug 12, 2013
Appl. No.:
13/964484
Inventors:
Adam D. Hughes - Belmont CA, US
Yan Chen - Foster City CA, US
John R. Jacobsen - San Mateo CA, US
Eric L. Stangeland - Pacifica CA, US
Rose Yen - San Francisco CA, US
Yan Chen - Foster City CA, US
John R. Jacobsen - San Mateo CA, US
Eric L. Stangeland - Pacifica CA, US
Rose Yen - San Francisco CA, US
Assignee:
THERAVANCE, INC. - South San Francisco CA
International Classification:
C07D 401/12, A61K 45/06, A61K 31/4709
US Classification:
514171, 546157, 514312
Abstract:
This invention relates to a compound of formula I:
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
8343954, Jan 1, 2013
Filed:
Jul 27, 2011
Appl. No.:
13/192344
Inventors:
Hui Li - Santa Clara CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Darren John McMurtrie - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
Thilo J. Heckrodt - San Francisco CA, US
Yan Chen - Foster City CA, US
Darren John McMurtrie - Foster City CA, US
Vanessa Taylor - San Francisco CA, US
Rajinder Singh - Belmont CA, US
Pingyu Ding - Foster City CA, US
Rose Yen - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/132, A61K 31/505, A61K 31/55, A61K 31/535, C07D 243/12, C07D 405/12, C07D 413/12
US Classification:
51421021, 514221, 5142338, 5142345, 514275, 540556, 544122, 544324
Abstract:
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.